Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis

被引:1
|
作者
Greco, Giuliana [1 ,2 ]
Sarpietro, Maria Grazia [2 ,3 ]
机构
[1] Univ Catania, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy
[2] Univ Catania, NANOMED Res Ctr Nanomed & Pharmaceut Nanotechnol, I-95125 Catania, Italy
[3] Univ Catania, Dept Drug & Hlth Sci, I-95125 Catania, Italy
来源
MOLECULES | 2024年 / 29卷 / 19期
关键词
multiple sclerosis; BBB; EAE models; nanocarriers; liposomes; drug delivery; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; GUINEA-PIGS; FATTY-ACID; T-CELLS; MYELIN; SUPPRESSION; PATHOGENESIS; INFLAMMATION; ANTIBODIES; PEPTIDE;
D O I
10.3390/molecules29194689
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the nervous system that leads to neurological dysfunctions and severe disabilities. It is worth noting that conventional pharmacotherapy is poorly selective and causes toxicity problems and several systemic side effects. Thus, there is a need to develop new approaches to this medical challenge. The use of nanocarriers for drug delivery represents a good strategy to overcome several issues such as high therapeutic drug doses with side effects, such as diarrhea, nausea, and abdominal pain, and drug degradation processes; in addition, nanocarriers can provide controlled and targeted drug release. This review describes the application of liposomes for the delivery of pharmaceutical actives to target MS. Firstly, MS is explained. Then, liposomes are described along with their preparation, characterization, and stability. The literature about the use of liposomes for the treatment of MS is then analyzed.
引用
收藏
页数:22
相关论文
共 50 条
  • [41] Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis
    Kvistad, Silje Stokke
    Myhr, Kjell-Morten
    Holmoy, Trygve
    Benth, Jurate Saltyte
    Wergeland, Stig
    Beiske, Antonie G.
    Bjerve, Kristian S.
    Hovdal, Harald
    Midgard, Rune
    Sagen, Jorn, V
    Torkildsen, Oivind
    JOURNAL OF NEUROIMMUNOLOGY, 2018, 323 : 73 - 77
  • [42] Potential application of hydrogel to the diagnosis and treatment of multiple sclerosis
    Liu, Haochuan
    Chen, Bing
    Zhu, Qingsan
    JOURNAL OF BIOLOGICAL ENGINEERING, 2022, 16 (01)
  • [43] Teriflunomide for the treatment of multiple sclerosis
    Warnke, Clemens
    Stueve, Olaf
    Kieseier, Bernd C.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S90 - S94
  • [44] The basis for treatment in multiple sclerosis
    Compston, A
    ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 : 41 - 47
  • [45] Multiple Sclerosis: Pathogenesis and Treatment
    Loma, Ingrid
    Heyman, Rock
    CURRENT NEUROPHARMACOLOGY, 2011, 9 (03) : 409 - 416
  • [46] Immune modulating peptides for the treatment and suppression of multiple sclerosis
    Badawi, Ahmed H.
    Siahaan, Teruna J.
    CLINICAL IMMUNOLOGY, 2012, 144 (02) : 127 - 138
  • [47] Liposome-based drug delivery to alveolar macrophages
    Vyas, Suresh P.
    Khatri, Kapil
    EXPERT OPINION ON DRUG DELIVERY, 2007, 4 (02) : 95 - 99
  • [48] Gut flora in multiple sclerosis: implications for pathogenesis and treatment
    Zhang, Weiwei
    Wang, Ying
    Zhu, Mingqin
    Liu, Kangding
    Zhang, Hong-Liang
    NEURAL REGENERATION RESEARCH, 2024, 19 (07) : 1480 - 1488
  • [49] The future of multiple sclerosis treatment
    Cohen, Jeffrey A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 277 : S55 - S61
  • [50] Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis
    Dinter, H
    Onuffer, J
    Faulds, D
    Perez, HD
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (02): : 95 - 102